Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Best-selling author, UNC alum Kristy Woodson Harvey delivers speech at New Student Convocation
The class of 2030 and transfer students gathered for New Student Convocation, where bestselling author and UNC alumna Kristy Woodson Harvey delivered a keynote address,...
Thu Sep 3, 2026

UNC football optimism flows - along with the beer - as Tar Heels take Dublin
It started out as a means of following a country star. Well, Chase Rice wasn’t a country star yet when Sophie Watkeys, 32, first started...
Wed Sep 2, 2026

UNC Libraries is Home to a Special Dolly Parton Recording. Here’s What to Know
People across the United States and around the world are mourning country music legend and philanthropist Dolly Parton, who died on Tuesday at 80 years...
Mon Aug 31, 2026

The Emerald Isle now touched with Carolina Blue
University of North Carolina at Chapel Hill chancellor Lee H. Roberts looked around in wonder at the sanctuary of the 800-year-old St. Patrick’s Cathedral in...
Sun Aug 30, 2026